Oxycodone Drugs Global Market Report 2024

The oxycodone drugs market size has grown strongly in recent years. It will grow from $5.25 billion in 2023 to $5.62 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to marketing of the drug for chronic non-malignant pain and cancer, aggressive marketing campaign for oxycontin, the number of oxycontin prescriptions for non-cancer-related pain, and entry of synthetic opiates such as oxycodone into the market in greater numbers.

The oxycodone drugs market size is expected to see strong growth in the next few years. It will grow to $7.41 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The anticipated expansion in the forecast period can be credited to several factors, including the escalating prevalence of chronic pain, a surge in surgical interventions, ongoing enhancements in product development poised to stimulate growth, advancements in drug delivery mechanisms, and a globally increasing aging demographic experiencing heightened instances of chronic pain. Significant trends expected in the forecast period encompass heightened demand for abuse-deterrent formulations (ADFs), the emergence of innovative delivery systems, a growing inclination towards combination therapies, and technological progressions in manufacturing.

The considerable prevalence of orthopedic disorders is poised to drive the expansion of the oxycodone drug market in the foreseeable future. Orthopedic disorders encompass various musculoskeletal conditions affecting bones, joints, ligaments, tendons, and muscles, often resulting in pain, restricted mobility, and functional impairments. The escalating occurrence of orthopedic disorders can be attributed to factors such as aging demographics, sedentary lifestyles, obesity, sports-related injuries, and occupational risks. Oxycodone drugs play a crucial role in managing orthopedic disorders by alleviating both acute and chronic pain associated with conditions such as fractures, joint injuries, or post-surgical recovery, offering effective relief through modulation of pain receptors in the central nervous system. For example, data from the Institute for Health Metrics and Evaluation, a US-based research institute, projects a substantial increase of approximately 115% (with a range of 107-124%) in musculoskeletal disorder cases (orthopedic disorders) from 2020 to 2050, reaching an estimated 1.06 billion prevalent cases by 2050. Hence, the substantial burden of orthopedic disorders underpins the growth trajectory of the oxycodone drug market.

Major companies in the oxycodone drug market are concentrating their efforts on developing innovative medications, such as oxycodone immediate-release (IR) tablets, to mitigate drug abuse via injection and intranasal administration. Oxycodone immediate-release (IR) tablets are a formulation of the opioid analgesic oxycodone intended to deliver swift pain relief. For example, in July 2022, Protega Pharmaceuticals LLC, a US-based pharmaceutical firm, introduced RoxyBond (oxycodone) immediate-release (IR) tablets in the United States. RoxyBond has obtained approval from the U.S. Food and Drug Administration (FDA) as an opioid agonist for severe pain management when other treatment options are insufficient. RoxyBond is equipped with advanced technology to deter misuse and abuse, making it challenging to tamper with physically or chemically. Studies have shown that RoxyBond demonstrates reduced potential for abuse compared to traditional oxycodone tablets, as evidenced by lower ratings for drug liking and desire for repeat consumption.

In February 2023, UNC Kenan-Flagler Business School, a US-based institution specializing in the Business of Health (CBOH), collaborated with Acadia Healthcare to create a flexible opioid settlement playbook. This collaboration seeks to outline the most efficient strategies for communities to deploy opioid settlement funds, particularly as communities nationwide, including those in North Carolina, are receiving substantial allocations to bolster opioid recovery initiatives from legal settlements involving opioid manufacturers and pharmacy chains. Acadia Healthcare Company, Inc. is a US-based organization offering behavioral healthcare services.

Major companies operating in the oxycodone drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Purdue Pharma L.P, Endo International plc, Amneal Pharmaceuticals LLC, Mundipharma Pty Limited, Alkermes plc, Mallinckrodt Pharmaceuticals, Alvogen Group Inc., Collegium Pharmaceutical Inc., Lannett Company Inc., Acorda Therapeutics Inc., Camurus AB, Rhodes Pharmaceuticals L.P., KVK Tech Inc., Teikoku Pharma USA Inc., Manus Aktteva Biopharma LLP, Zyla Life Sciences.

North America was the largest region in the oxycodone drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxycodone drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oxycodone drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oxycodone drug is a powerful opioid analgesic prescribed mainly to alleviate moderate to severe pain. Classified as an opioid agonist, it operates on precise receptors in the brain and spinal cord, modifying the perception of pain. When used properly and under medical supervision, oxycodone serves as an efficient method for pain management.

The primary classifications of oxycodone drugs encompass short-acting and long-acting formulations. Short-acting variants offer prompt pain relief with a brief duration of effect, typically employed for addressing acute pain instances such as post-surgery discomfort or injury-related pain. Oxycodone drugs are available in tablet, capsule, and injectable forms, prescribed for indications such as neuropathic pain, musculoskeletal pain, cancer-related pain, postoperative discomfort, among others. Their distribution spans across hospital pharmacies, retail outlets, and online platforms.

The oxycodone drugs market research report is one of a series of new reports that provides oxycodone drugs market statistics, including oxycodone drugs industry global market size, regional shares, competitors with a oxycodone drugs market share, detailed oxycodone drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oxycodone drugs industry. This oxycodone drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oxycodone drugs market consists of sales of hydrocodone, morphine, codeine, fentanyl, and methadone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.